



JONES PHARMA INCORPORATED
1945 Craig Road, P.O. Box 46903
St. Louis, Missouri 63146
314 576-6100 Fax 314 469-5749
www.jmedpharma.com

March 8, 2001

John Jenkins, M.D. Acting Director
Division of Metabolism and Endocrine Drug Products (HFD-510)
Document Control Room 14B-19
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

**RE: General Correspondence to NDA 21-301
Levoxyl (levothyroxine sodium tablets, USP)**

Reference is made to our New Drug Application for Levoxyl (Levothyroxine Sodium Tablets, USP), NDA 21-301 and to IND 59,177.

On March 8, 2001 an amendment was submitted to IND 59,177 clarifying that responsibility for sample retention has been retained by Jones Pharma (Attachment 1). Retention samples for the studies conducted in support of NDA 21-301 are being properly stored at our company subsidiary JMI-Daniels Pharmaceuticals, Inc., 2540 26th Ave. N., St. Petersburg, Florida 33713.

If there are any questions concerning this matter or further clarification is required, please do not hesitate to contact me by telephone at (314) 576-6100 or by fax at (314) 205-9497.

Sincerely,

JONES PHARMA INCORPORATED
(A subsidiary of King Pharmaceuticals, Inc.)

Nancy Cafmeyer
Director, Regulatory Affairs